GlassScriptPhysician profile
Alan B Segal
NPI 1003816158
$2,228.31
in general payments reported to CMS, 2019-2025
29 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $91.73 · 2021: $236 · 2022: $569 · 2023: $565 · 2024: $225 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.11 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $383.99 | 2020-2025 | |
| Abbvie INC. | $230.16 | 2020-2023 | Lo Loestrin Fe, Orilissa |
| Aspira Women'S Health INC | $195.97 | 2021-2022 | |
| Astellas Pharma US INC | $142.02 | 2023-2024 | Veozah, Myrbetriq |
| Organon LLC | $128.19 | 2022-2025 | Nexplanon |
| Daiichi Sankyo INC. | $126.65 | 2019-2022 | |
| Evofem Biosciences, INC. | $122.08 | 2022-2025 | Solosec, Phexx, Phexxi |
| Myriad Women'S Health, INC. | $118.32 | 2023 | |
| Mayne Pharma Commercial LLC | $113.02 | 2019-2025 | |
| Pfizer INC. | $111.15 | 2019-2025 | |
| Exeltis, USA INC. | $90.11 | 2021-2025 | Slynd |
| Agile Therapeutics, INC. | $67.58 | 2021-2024 | Twirla |
| Biogen, INC. | $53.43 | 2025 | Zurzuvae |
| Scynexis, INC. | $50.40 | 2022 | |
| Sumitomo Pharma America, INC. | $43.61 | 2024-2025 | Myfembree |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $36.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $33.33 | 2019 | |
| Medtronic, INC. | $28.92 | 2021-2022 | |
| Sage Therapeutics, LLC | $25.70 | 2022 | |
| Duchesnay USA Incorporated | $17.65 | 2019 | |
| Exact Sciences Corporation | $17.06 | 2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $15.10 | 2023 | Accrufer |
| Minerva Surgical, INC | $15.02 | 2022 | |
| Lupin INC. | $13.55 | 2020 | |
| Hologic Sales and Service, LLC | $13.18 | 2024 | Acessa Provu System, Novasure |
| Amgen INC. | $12.49 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.01 | 2019 | |
| Coopersurgical, INC. | $10.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Segal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.